Phung Gip

Phung Gip is a seasoned professional in the field of translational medicine and cancer immunotherapy, currently serving as the Sr. Director and Head of Translational Medicine at Nkarta, Inc. since September 2021. With a robust background in research and development, Phung Gip previously held positions as Director of Cell Therapy at Nkarta, focusing on CAR NK and CAR T cell therapies, and Director of Biology at Rubryc Therapeutics, specializing in T cell and T regulatory cell research for cancer immunotherapy and autoimmune diseases. As a founding member and lead scientist at Forty Seven Inc., Phung Gip contributed to the development of macrophage-targeted therapies. Earlier roles included a scientist position at Silver Creek Pharmaceuticals, a postdoctoral researcher at Stanford University's Irv Weissman lab, a research fellow at the National Science Foundation, and a PhD candidate at the University of California, Berkeley. Phung Gip holds a PhD in Molecular and Cellular Biology from the University of California, Berkeley, and a Bachelor of Arts in Biology and French from Macalester College.